Buscar
Protalix Biotherapeutics Inc
PLXAñadir a la lista de seguimiento
2.395USD
+0.025+1.05%
Cierre 07-27 16:00（ET）Cotizaciones retrasadas 15 min
192.97MCap. mercado
12.40P/E TTM
Más Datos de Protalix Biotherapeutics Inc Compañía
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Información de Protalix Biotherapeutics Inc
Símbolo de cotizaciónPLX
Nombre de la empresaProtalix Biotherapeutics Inc
Fecha de salida a bolsaSep 06, 2010
Director ejecutivoBashan (Dror)
Número de empleados207
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 06
Dirección2 University Plaza
CiudadHACKENSACK
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísUnited States of America
Código postal07601
Teléfono12016969345
Sitio Webhttps://protalix.com/
Símbolo de cotizaciónPLX
Fecha de salida a bolsaSep 06, 2010
Director ejecutivoBashan (Dror)
Ejecutivos de Protalix Biotherapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.53M
+7.70%
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
310.50K
+2.42%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
232.30K
+10.76%
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
7.54K
+99.47%
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
7.50K
+99.47%
Mr. Gilad Mamlok
Mr. Gilad Mamlok
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
3.63K
--
Mr. Amos Bar Shalev
Mr. Amos Bar Shalev
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Eliot Richard Forster, Ph.D.
Dr. Eliot Richard Forster, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mike Moyer
Mr. Mike Moyer
Investor Relations
Investor Relations
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.53M
+7.70%
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
310.50K
+2.42%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
232.30K
+10.76%
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
7.54K
+99.47%
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
7.50K
+99.47%
Mr. Gilad Mamlok
Mr. Gilad Mamlok
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
3.63K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Protalix Biotherapeutics Inc?
Los cinco principales accionistas de Protalix Biotherapeutics Inc son: Mr. Dror Bashan
¿Cuántas instituciones poseen acciones de Protalix Biotherapeutics Inc (PLX)?
A fecha de 2026Q1, 193 instituciones poseen acciones de Protalix Biotherapeutics Inc, con un valor de mercado combinado de aproximadamente 19.91M, lo que representa el 24.71% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 2149424.00.